Lifetime Citizen Portal Access — AI Briefings, Alerts & Unlimited Follows
Committee hears testimony on psilocybin therapeutic pilot for veterans; agencies warn of federal limits and timeline
Loading...
Summary
HF 45‑77 (DE3) would create a licensed psilocybin therapeutic pilot program for qualifying conditions including PTSD. Testimony from researchers and advocates cited clinical promise and urged careful licensing; MDVA noted federal Schedule I status prevents use in state veterans homes and OCM requested time and resources for implementation planning.
Sponsors introduced House File 45‑77 (as amended by DE3) to establish a regulated psilocybin therapeutic access pilot in Minnesota, with special attention to veterans living with qualifying conditions such as treatment‑resistant PTSD, depression and substance use disorders.
Representative Reimer and co‑sponsor Representative Smith said the bill follows recommendations from the legislatively created Psychedelic Medicine Task Force and is intended to create a tightly supervised clinical pathway rather than broad legalization. "This is professional, this is controlled," Representative Reimer told the committee. Dr. Jessica Nielsen, who chaired the task force and led Minnesota’s first FDA and DEA‑approved psilocybin clinical trial, described the task force's 200‑page report and cited research suggesting therapeutic promise for psilocybin in conditions that have been difficult to treat.
Advocates and patients also testified. Jamie Coyle of the Psychedelic Access Project supported the bill’s safety features—medical screening, licensed facilitators and controlled administration—but warned that the bill’s timeline could delay meaningful access: as written the program might take up to two years to stand up and then run a three‑year pilot, producing final recommendations as late as 2031 and earliest practical patient access in mid‑2032 unless timelines are adjusted.
The Minnesota Department of Veterans Affairs said it "takes no position" on the bill but stressed a practical limit: psilocybin is a Schedule I substance under federal law and the department cannot provide the treatment in state veterans' homes because a substantial portion of those homes’ budgets is federally funded through the VA. MDVA noted residents who live in veterans homes would need referrals to licensed facilities outside those homes in order to participate.
The Office of Cannabis Management (OCM) told the committee it lacks existing therapeutic expertise and requested time to help design major structural components and resourcing. OCM noted a fiscal note was in progress for earlier bill versions and emphasized the need for adequate timeline and resourcing to implement licensing and oversight.
Members raised safety and implementation concerns, invoking past prescription rollouts in which aggressive marketing had unintended consequences. Vice Chair Olsen asked for careful, methodical review and for licensing standards that are medically rigorous without being so prescriptive that no facility can meet them (citing Oregon’s early licensing problems as a cautionary example). Sponsors described a three‑session clinical model—education and informed consent, supervised administration in a licensed facility, and integration follow‑up—and said licensed facilitators would supervise multi‑hour dosing sessions in approved medical settings rather than self‑administration.
After extensive testimony and member discussion, HF 45‑77 as amended (DE3) was laid over for further consideration. Committee members and sponsors emphasized continued conversation on timeline, licensing standards, fiscal impact and federal constraints as the bill is refined.
